Drug · DIN 02468239
LENVIMA
EACH 18 MG DAILY DOSE CONTAINS 1 X 10 MG CAPSULES AND 2 X 4 MG CAPSULES PER BLISTER
Yes: authorized and sold in Canada
Authorized, and the company reports that it sells it in Canada.
Status Marketed since May 8, 2018; first marketed May 8, 2018.
- Drug Identification Number (DIN)
- 02468239
- Company (DIN owner)
- Eisai LimitedWoodcliff Lake, New Jersey, United States
- Schedule
- Prescription
- Dosage form
- Capsule
- Route
- Oral
- Therapeutic class (ATC)
- Lenvatinib L01EX08
- Class
- Human
- Record last updated
- August 25, 2026
Active ingredients
As listed in the Drug Product Database.
| Ingredient | Strength | Per |
|---|---|---|
| LENVATINIB (LENVATINIB MESYLATE) | 18 MG | DOSE |
Notices of Compliance
Health Canada approvals that name this DIN.
- September 13, 2017: NOC 19793Supplement to a New Drug Submission (SNDS) · New indication for use in combination with everolimus for the treatment of patients with advanced renal cell carcinoma
Other DINs named LENVIMA
- DIN 02450291 · Marketed
- DIN 02450305 · Marketed
- DIN 02450313 · Marketed
- DIN 02450321 · Marketed
- DIN 02468220 · Marketed
- DIN 02484056 · Marketed
- DIN 02484129 · Marketed